Microbix Biosystems (MBX.TO) Stock Price
Microbix Biosystems Price
Revenue has compounded at 9.0% per year over the past 19 years to 18.59 M CAD. Earnings per share have grown at 91.3% per year over the last 11 years. Microbix Biosystems's net margin stands at -12.1%, down from 8.8% several years earlier. Analysts set a median price target of 0.51 CAD, implying 61.9% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Microbix Biosystems stock price
Microbix Biosystems business model & stock analysis
Frequently asked questions about Microbix Biosystems
Microbix Biosystems Inc is a leading biotechnology company with a robust business model focused on developing and commercializing innovative biological products. The company specializes in producing and marketing unique biological substances, such as antigens and quality assessment controls, for diagnostic testing and scientific research. Microbix Biosystems Inc leverages its extensive expertise in virology, immunology, and bioprocessing to provide high-quality products to diagnostic laboratories, biopharmaceutical companies, and research institutions worldwide. With a continued commitment to advancing healthcare and scientific research, Microbix Biosystems Inc has established a strong reputation as a trusted partner in the industry.
Microbix Biosystems Inc is primarily active in the fields of virology and molecular diagnostics.
The main competitors of Microbix Biosystems Inc in the market include companies such as Becton, Dickinson and Company (BD), Bio-Rad Laboratories, and Meridian Bioscience Inc.
Microbix Biosystems Inc is a well-established company with a rich history and background. Founded in 1988, Microbix has grown to become a leading provider of biological products and technologies worldwide. The company specializes in the development, manufacture, and distribution of biological materials used in the diagnostics, research, and quality control fields. With its state-of-the-art facilities and dedicated team of experts, Microbix has consistently delivered innovative solutions to the global life sciences industry. Their wide range of products and services includes viral antigens, quality assessment programs, and proficiency panels. Throughout its history, Microbix Biosystems Inc has remained committed to providing high-quality products and contributing to advancements in the healthcare sector.
Microbix Biosystems Inc, a leading life science company, has accomplished several significant milestones. Notably, the company successfully developed and launched key products in the virology industry, including Quality Assessment (QA) controls for viral diseases and viral antigens. Microbix Biosystems Inc also introduced innovative technologies like the Kinlytic Urokinase, a clot-dissolving agent. Through strategic partnerships, the company expanded its global presence and garnered recognition for its exceptional research and development capabilities. Furthermore, Microbix Biosystems Inc achieved ISO 13485 certification, validating its commitment to quality management systems. These achievements solidify the company's position as a prominent player in the biotechnology sector.
Microbix Biosystems Inc is primarily present in Canada, United States, Europe, and Asia.
Microbix Biosystems Inc represents the values of exceptional innovation, dedication to quality, and commitment to customer satisfaction. As a leading biotechnology company, Microbix is driven by a strong corporate philosophy centered on advancing human health through the development and production of high-quality diagnostic reagents and viral antigens. With a focus on continuous improvement, Microbix strives to deliver superior products and services to meet the evolving needs of the healthcare industry. By prioritizing research and development, along with stringent quality control measures, Microbix Biosystems Inc ensures its reputation as a trusted provider of essential biological products.
Analysts currently set an average price target of 0.51 CAD for the Microbix Biosystems stock (median: 0.51 CAD), implying +61.9 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Microbix Biosystems stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Microbix Biosystems to generate revenue of 11.55 M CAD and earnings per share of -0.01 CAD.
Converted at the current exchange rate, the Microbix Biosystems share trades at 0.20 EUR (0.31 CAD).
The Microbix Biosystems share (MBX.TO) is listed on 2 stock exchanges, including: Toronto (MBX.TO).
Microbix Biosystems Inc is a Toronto-based biotechnology company that focuses on researching, developing, and marketing diagnostic and therapeutic products. The company operates in three business areas: Diagnostic test systems, infectious diseases, and bioproducts.
The expected revenue of Microbix Biosystems is 11.55 M CAD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Microbix Biosystems is -1.39 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Microbix Biosystems is currently -31.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Microbix Biosystems stock.
The price-to-sales ratio (P/S) of Microbix Biosystems is currently 3.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Microbix Biosystems stock.
The Eulerpool Quality Score for Microbix Biosystems is 2/10.
The ISIN of Microbix Biosystems is CA59501P1045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Microbix Biosystems is 935162. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Microbix Biosystems is MBX.TO. The ticker symbol is used to trade Microbix Biosystems shares on the stock exchange.
Microbix Biosystems stock
Microbix Biosystems Peer Group
Microbix Biosystems Ticker
Microbix Biosystems FIGI
All fundamentals and in-depth analysis of Microbix Biosystems
Our stock analysis for Microbix Biosystems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Microbix Biosystems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.